At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 437 enrolled
Drug / intervention
ACR16 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Multinational, Randomised, Double-Blind, Parallel-Group Study Comparing ACR16 45 mg Once-Daily or Twice-Daily Versus Placebo for the Symptomatic Treatment of Huntington's Disease
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Apr 23, 2008·Updated Aug 29, 2023
In Brief
A Phase 3 clinical trial evaluating ACR16 and Placebo for Huntington's Disease. Completed, enrolled 437 participants across 31 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesAustria, Belgium, France, Germany, Italy, Portugal, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartApr 2008
Primary CompletionJun 2010
TodayJul 2026
First PostedApr 23, 2008
Enrollment StartApr 24, 2008
Primary CompletionJun 14, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.2 years ago
Interventions
ACR16drug
Capsules will be swallowed whole with water.
Placebodrug
Capsules will be swallowed whole with water.